Vertex Reports meta-analysis Data for Tirzepatide in Multiple myeloma

Vertex today announced meta-analysis results for tirzepatide in patients with multiple myeloma. The study demonstrated that tirzepatide reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of multiple myeloma and support the continued development of tirzepatide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.